Compare LOOP & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | ONCY |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.8M | 94.0M |
| IPO Year | 2010 | 2002 |
| Metric | LOOP | ONCY |
|---|---|---|
| Price | $1.30 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 42.2K | ★ 1.1M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.88 | $0.33 |
| 52 Week High | $2.29 | $1.51 |
| Indicator | LOOP | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 48.78 |
| Support Level | $1.17 | $0.94 |
| Resistance Level | $1.37 | $1.08 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 41.09 | 27.82 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.